- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about JNJ
Recent news which mentions JNJ
7 Dividend Stocks to Buy and Never Sell: January 2024 Edition
January 25, 2024
From InvestorPlace
The Analyst Verdict: Johnson & Johnson In The Eyes Of 12 Experts
January 24, 2024
Tickers
JNJ
From Benzinga
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
From Benzinga
What's Going On Johnson & Johnson Stock Today?
January 24, 2024
From Benzinga
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks
January 24, 2024
From Benzinga
Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High
January 24, 2024
From Benzinga
Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript
January 23, 2024
Tickers
JNJ
From Motley Fool
US Stocks Pause As Treasury Yields, Dollar Surge On Trimmed Fed Rate Cut Bets: What's Driving Markets Tuesday?
January 23, 2024
From Benzinga
Johnson & Johnson's Settlement For Talc Cancer Lawsuits Reaches $700M Settlement With US States
January 23, 2024
From Benzinga
What's Going On With Danish Healthcare Firm Genmab Stock?
January 23, 2024
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 23, 2024
From Benzinga
US Stocks Mixed; Johnson & Johnson Posts Upbeat Earnings
January 23, 2024
From Benzinga
Johnson & Johnson's Clock 12% Q4 Revenue Growth, Cancer and Crohn's Disease Drugs Account as Largest Sellers
January 23, 2024
From Benzinga
From Benzinga
US Stocks Prepare For Nervy Start Ahead of Netflix, TI Earnings: Analyst Says Cash Waiting On Sidelines Could Flood Street If This Happens
January 23, 2024
From Benzinga
2 Genius Safe Stocks to Buy for 2024 and Beyond
January 23, 2024
From Motley Fool
Earnings Scheduled For January 23, 2024
January 23, 2024
From Benzinga
Fear & Greed Index Remains In 'Greed' Zone; Dow Settles Above 38,000
January 23, 2024
From Benzinga
Verizon, Netflix And 3 Stocks To Watch Heading Into Tuesday
January 23, 2024
From Benzinga
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
January 22, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
From Benzinga
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
January 22, 2024
From Benzinga
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
January 22, 2024
From Benzinga
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
January 22, 2024
From Benzinga
I'm Putting My Cash Stockpile to Work on These 3 Stocks
January 21, 2024
From Motley Fool
Nearing Retirement? These Stocks Are as Safe as They Come
January 21, 2024
From Motley Fool
From Motley Fool
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
January 21, 2024
From Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
January 20, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.